Iovance Faces Critical Test as Q3 Earnings Approach

Today represents a pivotal moment for Iovance Biotherapeutics as the biotechnology firm prepares to release its third-quarter financial results before market opening. With shares having plummeted more than 85% over the past year, investor anxiety runs high regarding the company’s ability to stage a recovery.

Market expectations have reached their lowest ebb, with Wall Street analysts forecasting a loss per share ranging from $0.26 to $0.29. Revenue projections stand at approximately $76.2 million.

The company’s previous quarterly report delivered disappointing results, with Iovance missing both profit and revenue targets. Instead of the anticipated $0.29 loss per share, the company reported a $0.33 per share deficit. Revenue figures also fell short, reaching only $59.95 million Read more...